Pemurnian Antibodi Monoklonal terhadap Virus Hepatitis B yang diisolasi dari Asites Mencit Balb/c Menggunakan “Homemade” Protein A Spin Mini Kolom by Ngongu Depamede, Sulaiman
JURNAL KEDOKTERAN YARSI 20 (2) : 063-068 (2012)
Pemurnian Antibodi Monoklonal terhadap Virus Hepatitis
B yang diisolasi dari Asites Mencit Balb/c Menggunakan
“Homemade” Protein A Spin Mini Kolom
Purification of Monoclonal Antibody against Hepatitis B
Virus isolated from Balb/c Ascites Using “Homemade Protein
A Spin Mini-column”
Sulaiman Ngongu Depamede
Faculty of Animal Science and Immunobiology Laboratory, Mataram University
KATA KUNCI
KEYWORDS
ABSTRAK
ABSTRACT
Protein A; purifikasi; antibody monoclonal; hepatitis B; mini kolom
Protein A; purification; monoclonal antibody; hepatitis B; mini-column
Penelitian ini bertujuan mengembangkan pemurnian antibodi monoklonal
menggunakan eks-mini kolom yang isinya diganti dengan partikel gelas silika
yang terkonjugasi dengan Protein A. Matriks Protein A yang digunakan adalah
Prosep vA, sedangkan antibodi target adalah antibodi monoklonal (MAb)
terhadap antigen permukaan virus hepatitis B yang diisolasi dari asites mencit
Balb/c. Sebelum pemurnian, sampel asites dibagi menjadi 3 yang masing-
masing diinkubasikan dengan Protein A dalam 3 perlakuan. Perlakuan A dan B
adalah inkubasi 30 dan 60 menit pada suhu kamar, sedangkan perlakuan C
adalah inkubasi semalam pada suhu 4°C. Hasil pemurnian menunjukkan bahwa
aktivitas spesifik dan tingkat kemurnian MAb secara berurutan adalah 358.45
U/mg, 237.83 U/mg untuk perlakuan C dan B, dan 229.67 U/mg untuk
perlakuan A. Hasil penelitian ini menunjukkan bahwa 'homemade' mini kolom
yang dikembangkan dalam penelitian ini dapat digunakan untuk memurnikan
MAb untuk kebutuhan riset skala laboratorium.
This study was aimed to develop a reliable antibody purification technique using
the ex-mini-columns in which its content was replaced with silica glass Protein
A conjugated. Protein A matrix used was Prosep vA, whereas the target
antibody was a monoclonal antibody (MAb) against hepatitis B virus surface
antigen from the ascites of Balb/c mice. Prior to purification of the ascites,
samples were incubated with Protein A in three different treatments. Treatment
A and B were 30 and 60 minutes incubation time at room temperature, and
treatment C with overnight incubation at 4°C. The results showed that the
specific activity and the purity level of the MAb obtained from the studies were
358.45 U/mg, 237.83 U/mg and 229.67 U/mg for treatment C, B and A,
respectively. These results indicated that the 'homemade' mini-column
developed in this study can be used to purify MAb to the needs of the
laboratory-scale research.
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Antibody(ies) with sufficient purity is
necessary and needed in immunological
research activities. For this purpose a variety
of procedures or methods to isolate and
purify antibody in order to get not only
optimum activity but also efficient and
economical values has been done. Purification
of antibody using Protein A attached to a
variety of matrices such as silica glass is one
of the methods of separation and purification
commonly used. This is due to the nature of
the Protein A (42 kDa), a protein of the
bacterium Staphylococcus aureus, which can
bind to the Fc arms of immunoglobulin,
especially IgG (Graille et al., 2000; Liu et al.,
2010).
Protein A column of silica glass is
commonly used for antibody purification in
small or even large scale and available on the
market. In certain circumstances, particularly
in several laboratories such as those in
Indonesia, a bench top small-scale
purification method with optimal results is
needed. Therefore research on the
development of small-scale antibody
purification method using homemade Protein
A column was conducted.
In this study monoclonal antibody
against the surface antigen of Hepatitis B
virus (HBsAg) from mouse ascites was used.
Hepatitis is still considered as a serious health
problem in the world with more than 350
million people infected with hepatitis B virus
(HBV), some of them will have cirrhosis and
liver cancer (Mulyanto et al., 2011). The
prevalence of HBV infection is generally high
in Asia and Africa, with most infections
develop at birth or during childhood (Lee,
1997). In Indonesia, the prevalence of HBV
infection is different in each region with a
relatively high population of HBV carriers,
about 4.0 to 20.3% (Khan et al., 2004).
Until now there has been no effective
drug available to treat HBV infected persons.
WHO recommends early immunization as
the most efficient means to prevent
transmission of HBV (McMahon, 2005). In
addition, screening for the blood donor on a
regular basis is important as well. To support
all of these, reliable and accountable
diagnostic kits are necessary to be available.
Consequently, research to ensure continuous
availability of antibodies, including antibody
purification process is needed.
This paper reports the success of
developing a "homemade Protein A mini-
column" to isolate and purify monoclonal
antibody against HBV antigen from ascites of
Balb/c mice.
MATERIALS AND METHODS
Materials
Antibodies used in this study were
monoclonal antibody (MAb) specific for
hepatitis B virus surface antigen (HBsAg),
derived from ascites fluid of Balb/c mice.
This MAb (Lot. KO436) is produced in the
Laboratory of Hepatitis Nusa Tenggara Barat.
Mini-column used was a 2 ml plastic mini-
column regenerated from Invitrogen (Esser et
al., 2005). The used silica in the tube was
removed and replaced with 250 µl fresh glass
silica Protein A (Prosep vA, Millipore).
Preparation of Buffers
Buffer used consisted of buffer A
(washing buffer) 500 mM NaCl containing
100 mM Na2HPO4-12H2O pH 8.5, buffer B
(sample dilution) 1 M NaCl containing 200
mM Na2HPO4-12H2O pH 8.5, and buffer C
(elution buffer) 150 mM NaCl containing 100
mM Citric acid, pH 3, and neutralization
solution 2 M Tris. Chemicals were purchased
from Merck, Germany.
Purification process was initiated by
diluting the sample (4 times dilution) of
ascites fluid containing monoclonal antibody
using buffer B. Subsequently the diluted
samples were divided into 3 treatment
groups (A, B, and C). One ml of diluted
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sample from each group was mixed with 250
µl of Protein A conjugated glass silica in a 1.5
ml micro tube. Micro tubes were assigned for
group A, B and C, representing incubation
time for the mix between Protein A
conjugated silica and ascites fluid for 30 and
60 minutes at room temperature and
overnight at 4ºC, respectively.
Following the incubation, the silica
and samples of representative group was
transferred and loaded into the mini-column
placed into a collection tube, and then
centrifuged using a micro centrifuge (TOMY,
MC-140, Japan) for 1 minute, at room
temperature with maximum speed. The flow-
through (FT-1) was collected and the
collection tubes were assigned in accordance
to the treatment group and purification step
(Table 1, 2 and 3). Then, the column was
washed twice, firstly with 500 µl and then 3
ml of buffer A. The flow-through was
collected and assigned as FT-2 and FT-3
respectively. After washing with buffer C, the
target antibody was removed with elution
buffer and the flow-through was collected
(assigned as Elutant) and neutralized with 2
M Tris. All of the procedures were repeated 3
times for all treatment groups. The whole
flow-through collected was kept at 4ºC until
assayed for their antibody activities, protein
concentration and purity.
Assay for Antibody Activity
The antibody activities were assessed
by passive hem-agglutination (PHA) method
using the Kit "Entebe" PHA-Cell
(Laboratorium Hepatika, NTB, Indonesia)
according to the manufacturer's instructions,
without any modification.
Protein Determination
Protein (antibody) determinations
were carried out using Bradford microassay
method in accordance with the
manufacturer's instructions. Bovine serum
albumin (BSA) was used as standard. A total
of 100 µl standard or sample was mixed with
1 ml of Bradford reagent then the absorbance
changes were read using UV-Vis
Spectrophotometer (Shimadzu, Japan) at a
wavelength of 595 nm. Antibody
concentration was calculated by interpolation
of standard curves.
Data Analysis
The data obtained were tabulated and
analyzed according to Depamede and
Rosyidi (2009) and calculation for the
recovery, activity and purity of the antibody
throughout the purification steps were based
on Xiao-lan et al., (2005).
RESULTS
The aim of this study was to develop
methods of isolation and purification of the
antibody in a small scale using a mini-column
of “homemade protein A glass silica”. The
results of the purification process are
presented in Tables 1, 2 and 3 with the
representation of each treatment of 30 and 60
minutes incubation time at room temperature
and overnight at 4ºC respectively.
066 SULAIMAN NGONGU DEPAMEDE
Table 1. Antibody recovery and activity during purification process using homemade
Protein A mini-column with 30 minutes incubation at room temperature
Purification
Step
Tot.Vol.
(ml)
Prot.Cons.
(mg/ml)
Total
Prot.
(mg)
Total
Activity
(Unit)
Specific
Activity
(U/mg)
Purification
(fold)
%
Recovery
Ascites 1.00 2.04 2.04 15.50 7.61 1.00 100.00
FT-1 0.80 1.39 1.11 9.00 8.10 1.06 58.06
FT-2 0.50 0.47 0.24 11.00 46.45 6.10 70.97
FT-3 3.00 0.06 0.18 11.00 60.80 7.98 70.97
Eluting 0.25 0.19 0.05 11.17 229.67 30.16 72.04
FT: Flow through
Table 2. Antibody recovery and activity during purification process using homemade
Protein A mini-column with 60 minutes incubation at room temperature
Purification
Step
Tot.Vol.
(ml)
Prot.Cons.
(mg/ml)
Total
Prot.
(mg)
Total
Activity
(Unit)
Specific
Activity
(U/mg)
Purification
(fold)
%
Recovery
Ascites 1.00 2.04 2.04 15.50 7.61 1.00 100.00
FT-1 0.80 1.48 1.19 11.00 9.27 1.22 70.97
FT-2 0.50 0.39 0.20 11.00 55.94 7.35 70.97
FT-3 3.00 0.10 0.20 11.00 55.61 7.31 70.97
Eluting 0.25 0.24 0.06 14.50 237.83 31.86 94.62
FT: Flow through
Table 3. Antibody recovery and activity during purification process using homemade
Protein A mini-column with overnight incubation at 4°C
Purification
Step
Tot.Vol.
(ml)
Prot.Cons.
(mg/ml)
Total
Prot.
(mg)
Total
Activity
(Unit)
Specific
Activity
(U/mg)
Purification
(fold)
%
Recovery
Ascites 1.00 2.04 2.04 15.50 7.61 1.00 100.00
FT-1 0.80 1.29 1.04 10.00 9.65 1.27 64.52
FT-2 0.50 0.30 0.15 10.00 67.29 8.84 64.52
FT-3 3.00 0.02 0.05 10.00 204.67 26.88 64.52
Eluting 0.25 0.15 0.04 13.50 358.45 47.08 87.10
FT: Flow through
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DISCUSSION
Currently a lot of kits for isolating
antibodies are available in the market
(Berruex et al., 2000) but in some
circumstances when we want to do the
isolation and purification of antibody in
small-scale, some technical constraints are
often encountered. On the other hand,
antibody with sufficient purity for bench-top
experiments is truly needed.
In general the “homemade Protein A
mini-column” was successfully used to
isolate the antibody derived from ascites in a
small scale volume. As presented in Tables 1,
2 and 3, if we look closer at the recovery,
which was the percentage of total activity of
purified MAb against the total activity of
crude MAb, the highest yield was obtained
when the antibody exposed or incubated for
60 minutes with Protein A glass silica at room
temperature prior to further purification
process. Subsequent level of recovery was
derived from the overnight incubation time at
4ºC and for 30 minutes at room temperature,
respectively.
Considering the antibody specific
activity, overnight incubation time at 4ºC was
superior (358.45 U/mg) compared to the
other treatments (i.e. 237.83 and 229.67 U/mg
for 60 and 30 minutes at room temperature
respectively). The specific activity was also
corresponding to antibody purity i.e. 47.08,
31.86 and 30.16 folds. Although a recovery
percentage of 94.62% by incubation time of 60
minutes was obtained, it did not remove
many proteins (Mondal and Gupta, 2006) that
might interfere further usage of the antibody
compared to the overnight incubation times
with more pure yield. Ideally, we expected to
get high recovery with high specific activity
and purest antibody as well. However, this is
actually quite a compromise. If the processing
time limit is not an issue and the degree of
purity is preferred, then the overnight
incubation protocol is the right choice.
What can be obtained from the results
of this study is that we can take advantage of
the used mini-column and replace its content
with a fresh silica glass conjugated with
Protein A to purify monoclonal antibody.
Furthermore, the silica can also be
regenerated (Esser et al., 2005), hence the
protocol would be quite helpful, especially
for a small laboratory for their bench-top
experiments. But it is certain that further
comprehensive studies need to be done.
CONCLUSION
Monoclonal antibody against hepatitis
B virus has been successfully isolated from
mouse ascites using “homemade Protein A
spin mini-column” developed in this study.
The spin mini-column can be used to purify
monoclonal antibody to the needs of the
laboratory-scale researches.
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